Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

Simonds, 1998, Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy, Thorax, 53, 949, 10.1136/thx.53.11.949 Eagle, 2002, Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation, Neuromuscul Disord, 12, 926, 10.1016/S0960-8966(02)00140-2 Hoffman, 1987, Dystrophin: the protein product of the Duchenne muscular dystrophy locus, Cell, 51, 919, 10.1016/0092-8674(87)90579-4 Morris, 1993, A quantitative ELISA for dystrophin, J Immunol Methods, 161, 23, 10.1016/0022-1759(93)90194-C Koenig, 1989, The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion, Am J Hum Genet, 45, 498 Bushby, 1993, The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II Correlation of phenotype with genetic and protein abnormalities, J Neurol, 240, 105, 10.1007/BF00858726 Klein, 1992, Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers, Am J Hum Genet, 50, 950 Lu, 2000, Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion, J Cell Biol, 148, 985, 10.1083/jcb.148.5.985 Melis, 1998, Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families, Eur J Paediatr Neurol, 2, 255, 10.1016/S1090-3798(98)80039-1 Lesca, 2007, Family study allows more optimistic prognosis and genetic counselling in a child with a deletion of exons 50–51 of the dystrophin gene, Arch Pediatr, 14, 262, 10.1016/j.arcped.2006.11.025 Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, Lancet Neurol, 2, 731, 10.1016/S1474-4422(03)00585-4 Aartsma-Rus, 2009, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, Hum Mutat, 30, 293, 10.1002/humu.20918 Sazani, 2008, Splice switching oligonucleotides as potential therapeutics, 89 Aartsma-Rus, 2003, Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients, Hum Mol Genet, 12, 907, 10.1093/hmg/ddg100 Aartsma-Rus, 2007, Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications, RNA, 13, 1609, 10.1261/rna.653607 McClorey, 2006, Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD, Gene Ther, 13, 1373, 10.1038/sj.gt.3302800 Lu, 2003, Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse, Nat Med, 9, 1009, 10.1038/nm897 Yokota, 2009, Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs, Ann Neurol, 65, 667, 10.1002/ana.21627 Takeshima, 2006, Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy, Pediatr Res, 59, 690, 10.1203/01.pdr.0000215047.51278.7c van Deutekom, 2007, Local dystrophin restoration with antisense oligonucleotide PRO051, N Engl J Med, 357, 2677, 10.1056/NEJMoa073108 Sazani, 2002, Systemically delivered antisense oligomers upregulate gene expression in mouse tissues, Nat Biotechnol, 20, 1228, 10.1038/nbt759 Fletcher, 2006, Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide, J Gene Med, 8, 207, 10.1002/jgm.838 Alter, 2006, Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology, Nat Med, 12, 175, 10.1038/nm1345 Heemskerk, 2009, In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping, J Gene Med, 11, 257, 10.1002/jgm.1288 Muntoni, 2008, 149th ENMC International Workshop and 1st TREAT-NMD Workshop on: planning phase I/III clinical trials using systemically delivered antisense oligonucleotides in Duchenne muscular dystrophy, Neuromuscul Disord, 18, 268, 10.1016/j.nmd.2007.11.010 Emery, 2003 Mercuri, 2002, Muscle MRI findings in a three-generation family affected by Bethlem myopathy, Eur J Paediatr Neurol, 6, 309, 10.1016/S1090-3798(02)90618-5 Hawley, 1984, Computed tomographic patterns of muscles in neuromuscular diseases, Arch Neurol, 41, 383, 10.1001/archneur.1984.04050160045014 Dubowitz, 2007 Macalister, 1875, Additional observation on muscular anomalies in human anatomy (third series), with a catalogue of the principal muscular variations hitherto published, Trans Roy Irish Acad Sci, 25, 1 Mercuri, 2007, Muscle MRI in inherited neuromuscular disorders: past, present, and future, J Magn Reson Imaging, 25, 433, 10.1002/jmri.20804 Mercuri, 2002, A short protocol for muscle MRI in children with muscular dystrophies, Eur J Paediatr Neurol, 6, 305, 10.1016/S1090-3798(02)90617-3 Bailey, 1987, The use of social stress and support interview in families with deviant children: methodological issues, Social Psychiatry, 22, 209, 10.1007/BF00583556 Goodman, 2000, Using the Strengths and Difficulties questionnaire to screen for child psychiatric disorders, Br J Psychiatry, 177, 534, 10.1192/bjp.177.6.534 Goldberg, 1978 Miller, 1985, The McMaster Family Assessment Device: Reliability and Validity, J Marital Fam Ther, 11, 345, 10.1111/j.1752-0606.1985.tb00028.x White, 1999, Validation of the Hospital Anxiety and Depression Scale for use with adolescents, Br J Psychiatry, 175, 452, 10.1192/bjp.175.5.452 Roest, 1996, Application of in vitro Myo-differentiation of non-muscle cells to enhance gene expression and facilitate analysis of muscle proteins, Neuromuscul Disord, 6, 195, 10.1016/0960-8966(96)00006-5 Arechavala-Gomeza, 2007, Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle, Hum Gene Ther, 18, 798, 10.1089/hum.2006.061 Ferrer, 2004, Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins, Gene Ther, 11, 884, 10.1038/sj.gt.3302242 Nguyen, 1993, Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy, Am J Hum Genet, 52, 1057 Neri, 2007, Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human, Neuromuscul Disord, 17, 913, 10.1016/j.nmd.2007.07.005